Taken together these and other data suggest that circulating levels of SHBG are a marker of the presence and severity of hepatic insulin resistance [3], de novo lipogenesis [10], and associated conditions including NAFLD [5], type 2 diabetes [10], and cardiovascular disease [7]. This evidence concerns the gene SHBG and metabolic dysfunction-associated steatotic liver disease.